Episode 305: The FDA and Oncology Clinical Trials

FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials, including approaches to control arms in phase 3 trials and how results from multiple trials are considered. He also highlights the different approaches between accelerated and traditional approval.

Dr. Suzman is a medical oncologist, and serves as deputy director of the Divison of Oncology 1 at the FDA, which focuses on GU malignancies, breast cancer, and gynecological malignancies.